"Happy birthday to my favorite person to do nothing, and everything, with," Meyer wrote alongside a sweet photo carousel featuring Stewart, who turned 35 Dylan Meyer/Instagram Happy birthday ...

Jazz Pharmaceuticals Plc said it will pay $145 million to resolve antitrust litigation accusing the company of colluding to delay the generic version of its brand-name narcolepsy drug Xyrem. Jazz ...

Amid a broader selloff in the biopharma sector on Wednesday, Jazz Pharmaceuticals (NASDAQ:JAZZ) dropped ~6% after announcing a $145M settlement to resolve certain antitrust claims filed regarding ...

Share price of JAZZ Pharmaceuticals JAZZ hit $102.82 on Tuesday, close to its 52-week low of $99.06. This decline is attributable to the significant downturn in the broader biotech/drug sector due ...

In remarks before the National Republican Congressional Committee, Trump said his administration will “be announcing very shortly a major tariff on pharmaceuticals” made abroad. While pharmaceuticals ...

Avadel has initiated four patent infringement lawsuits against Jazz Pharmaceuticals since the beginning of 2025, alleging certain uses of Jazz’s Xywav product, according to its corresponding labeling, ...

In a high-stakes twist in the pharmaceutical legal arena, Jazz Pharmaceuticals has agreed to shell out a staggering $145 million to settle claims that it orchestrated an anticompetitive scheme with ...

Jazz Pharmaceuticals will pay $145 million to settle allegations of anti-trust practices related to its narcolepsy drug Xyrem, according to an SEC filing on Tuesday. The settlement, which is still ...

President Donald Trump assured Republicans that his “Liberation Day” tariffs will have a positive impact, teasing coming levies on pharmaceuticals as well. Speaking at the National Republican ...

April 8 (Reuters) - Jazz Pharmaceuticals (JAZZ.O), opens new tab said on Tuesday that it had agreed to a settlement of $145 million to resolve a series of antitrust lawsuits related to its ...